Oncotarget

Research Papers:

LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling

Ye Liu, Zhaoyang Wang, Di Huang, Chao Wu, Huihui Li, Xin Zhang, Bin Meng, Zongjin Li, Tianhui Zhu, Shuang Yang and Wei Sun _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:9513-9524. https://doi.org/10.18632/oncotarget.13434

Metrics: PDF 1776 views  |   HTML 2260 views  |   ?  


Abstract

Ye Liu1, Zhaoyang Wang1, Di Huang1, Chao Wu1, Huihui Li1, Xin Zhang2, Bin Meng3, Zongjin Li4, Tianhui Zhu1, Shuang Yang1, Wei Sun1

1Laboratory of Molecular Genetics in School of Medicine, Nankai University, Tianjin, China

2Department of Histology and Embryology in School of Medicine, Nankai University, Tianjin, China

3Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

4Laboratory of Stem cells in School of Medicine, Nankai University, Tianjin, China

Correspondence to:

Wei Sun, email: sunweibio@nankai.edu.cn

Shuang Yang, email: yangshuang@nankai.edu.cn

Keywords: LMO2, actin filament, basal-type breast cancer, metastasis, cofilin1

Received: April 20, 2016    Accepted: November 02, 2016    Published: November 17, 2016

ABSTRACT

LMO2 is traditionally recognized as a pivotal transcriptional regulator during embryonic hematopoiesis and angionenesis, and its ectopic expression in T lymphocyte progenitors is closely correlated to the onset of acute T lymphocytic leukemia. However, recently studies revealed complicated expression features and dual functions of LMO2 on tumor behaviors in a variety of cancer types, including breast cancers. Basal-type breast cancer is one of the breast cancer subtypes and a prognostically unfavorable subtype among all breast cancers. Herein we found that in basal-type breast cancer specifically, high LMO2 expression was positively correlated with lymph node metastases in patients, promoted tumor cell migration and invasion and increased distant metastasis in SCID mice. Moreover, the novel function of LMO2 was achieved by its predominantly cytoplasmic location and interaction with cofilin1, which is a critical regulator in actin cytoskeleton dynamics. These findings suggest a subtype-dependent role of LMO2 in breast cancers and the potential of LMO2 as a subtype-specific biomarker for clinical practice.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13434